EXPERIMENTAL STUDY OF THE SPECIFIC IMMUNOLOGICAL ACTIVITY AND SAFETY OF THE DRUG "CORONADERM-PS" TO EVALUATION OF CELLULAR IMMUNITY AGAINST SARS-CoV-2
EXPERIMENTALLY INVESTIGATED "CORONADERM-PS"-DRIVEN SARS-CoV-2-SPECIFIC CELLULAR IMMUNITY AND SAFETY
- Authors:
Savin T.V.1,2, Kopat V.V.3, Riabchenkova A.A.3, Chirak E.L.3, Chirak E.R.3, Saenko A.I.3, Dukhovlinov I.V.3, Sysoeva G.M.4, Gamaley S.G.4, Shimina G.G.4, Taranov O.S.5, Danilenko E.D.5, Totolian A.A.1,2, Simbirtsev A.S.1,2
-
Affiliations:
- Saint-Petersburg Pasteur Institute
- Pavlov First Saint Petersburg State Medical University, department of Immunology
- ATG Service Gene LLC, St. Petersburg, Russian Federation
- State Research Center of Virology and Biotechnology VECTOR, Department of Biological research
- State Research Center of Virology and Biotechnology VECTOR, Department of Microscopic Research
- Section:
ORIGINAL ARTICLES
- Submitted: 13.05.2024
- Accepted: 15.05.2024
- Published:
Email this article